• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.

    11/12/25 6:14:59 PM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Anteris Technologies Global Corp.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    03675P102

    (CUSIP Number)


    10/29/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03675P102


    1Names of Reporting Persons

    L1 Capital Pty Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    8,219,814.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    8,219,814.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,219,814.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.9 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Anteris Technologies Global Corp.
    (b)Address of issuer's principal executive offices:

    Toowong Tower, Level 3, Suite 302, 9 Sherwood Road, Toowong, QLD, Australia
    Item 2. 
    (a)Name of person filing:

    L1 Capital Pty Ltd.
    (b)Address or principal business office or, if none, residence:

    Level 45 101 Collins Street Melbourne VIC 3000, C3 00000
    (c)Citizenship:

    Australia
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    03675P102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    8,219,814 This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on January 23, 2025, covering 6,741,401 shares of Common Stock purchased on December 16, 2024. The amount in Rows (5), (7) and (9) consists of 8,219,814 shares of common stock owned by the L1 Long Short Fund Limited, the L1 Capital Long Short Fund, the L1 Capital Long Short (Master) Fund, the L1 Capital Global Champions Fund Fund, and the L1 Capital Global Long Short (Master) Fund, all controlled and managed by L1 Capital Pty Ltd. The percentage set forth on Row (11) of the cover page for the reporting person is based on 41,197,570 shares of Common Stock outstanding as of November 11, 2025, based on an email communication from the Issuer's Chief Financial Officer. Mark Landau is a Director of L1 Capital Pty Ltd. As such, he may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Landau is deemed to beneficially own such securities, he disclaims beneficial ownership of these securities for all other purposes.
    (b)Percent of class:

    19.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    8,219,814

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    8,219,814

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    L1 Capital Pty Ltd
     
    Signature:/s/ Mark Landau
    Name/Title:Mark Landau, Director
    Date:11/12/2025
    Get the next $AVR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.

    SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)

    11/12/25 6:14:59 PM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Anteris Technologies Global Corp.

    10-Q - Anteris Technologies Global Corp. (0002011514) (Filer)

    11/12/25 4:06:22 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.

    SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)

    11/12/25 8:00:21 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anteris Announces Results for the Third Quarter of 2025

    MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Highlights Continued FDA engagement during the Quarter to advance the IDE for the PARADIGM Trial, with FDA approval to commence U.S. recruitment* announced in November 2025Advanced European regulatory activities to initiate the PARADIGM Trial across

    11/12/25 5:52:49 PM ET
    $AVR
    Industrial Specialties
    Health Care

    FDA Approves Anteris's DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")

    PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and BRISBANE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Anteris announced today it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM, its global Investigational Device Exemption (IDE) clinical trial which is designed to evaluate the DurAVR® Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis and to support a future PMA* submission. "We are extremely pleased to receive FDA approval for the PARADIGM Trial, which allows us to commence pati

    11/3/25 7:00:00 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year

    MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm2). The DurAVR® THV System demonstrated single digit mean gradients and large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality at one year, with l

    10/28/25 6:08:22 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Moss Gregory S.

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    6/10/25 6:01:58 AM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Roberts David B

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    6/10/25 6:01:52 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Amendment: Director Seaberg John D exercised 40,000 shares at a strike of $7.13 and covered exercise/tax liability with 36,148 shares (SEC Form 4)

    4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)

    3/21/25 9:30:47 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

    Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

    1/8/25 8:52:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

    TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00

    1/7/25 9:02:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

    Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00

    1/7/25 9:00:55 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments